{"nctId":"NCT02301910","briefTitle":"Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI","startDateStruct":{"date":"2014-05-16","type":"ACTUAL"},"conditions":["Myocardial Infarction"],"count":382,"armGroups":[{"label":"Recombinant staphylokinase","type":"EXPERIMENTAL","interventionNames":["Drug: Recombinant staphylokinase"]},{"label":"Tenecteplase","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tenecteplase"]}],"interventions":[{"name":"Recombinant staphylokinase","otherNames":["Fortelyzin"]},{"name":"Tenecteplase","otherNames":["Metalyse"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* both gender patients over 18 years\n* 12-lead ECG indicative of an STEMI (ST-segment elevation in acute myocardial infarction, measured at the J point, should be found in two contiguous leads and be ≥0.25 mV in men below the age of 40 years, ≥0.2 mV in men over the age of 40 years, or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads (in the absence of left ventricular hypertrophy or left bundle branch block\n* the possibility of fibrinolysis within 12 hour of symptom onset\n* inability of primary PCI within 60 min of first medical contact (FMC)\n* informed consent received\n\nExclusion Criteria:\n\n* expected performance of PCI less 60 min from FMC\n* left bundle branch block or ventricular pacing\n* cases of sinus bradycardia associated with hypotension, AV block II (Mobitz 2) or AV block III with bradycardia that causes hypotension or heart failure\n* active bleeding or known bleeding disorders/diathesis\n* uncontrolled hypertension, defined us single blood pressure measurement ≥180/110 mm Hg prior to randomization\n* internal bleeding within the past 2 weeks\n* conditions with increased risk of bleeding (peptic ulceration)\n* prolonged or traumatic resuscitation within the past 2 weeks\n* any known history of hemorrhagic stroke, or transitory ischemic attack\n* ischemic stroke within the past 3 month\n* puncture of unpressable vessels\n* aortic aneurism\n* intracranial neoplasm\n* any head trauma within past 2 weeks\n* intracranial vessel malformation\n* recent administration of anticoagulant within the past month\n* INR \\>1.3\n* sensibilisation to staphylokinase\n* contra-indications to acetylsalicilic acid, clopidogrel, enoxaparin\n* any conditions with unfavorable prognosis\n* in case of surgical treatment required within 30 days after randomization\n* in case of unhallowed medications required\n* pregnancy, lactation\n* inability to follow the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Participants With Reperfusion","description":"The number of participants with reperfusion by TIMI (Thrombolysis in Myocardial Infarction) 2-3 assessed by coronary arteriography, where grade 0 - no perfusion, grade 1 - penetration without perfusion, grade 2 - partial perfusion, grade 3 - complete perfusion.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Endpoint","description":"All cause death+Reccurent MI+Stroke+Heart failure","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Cardiovascular Death","description":"Death caused by any cardiovascular reason/event","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Repeated Target Vessel Revascularization","description":"The need for re-intervention on infarct-related artery within 30 days after fibrinolysis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Development of Heart Failure","description":"In case of at least of the one of the following conditions:\n\n1. Pulmonary oedema/congestion on chest X-ray without suspicion of a non-cardiac cause\n2. Rales \\> 1/3 up from the lung base (Killip class 2 or higher)\n3. Pulmonary capillary wedge pressure (PCWP) \\>25 mmHg\n4. Dyspnoea with pO2 \\< 80 mmHg or O2 sat \\< 90 % (no supplemental O2) in the absence of known lung disease;","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Rehospitalization Due to Cardiovascular Reasons","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Bleeding","description":"GUSTO classification","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Intracranial Haemorrhages","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":191},"commonTop":["hematuria"]}}}